Silence Therapeutics plc (SLN) Stock Score, Valuation & Financial Research
Silence Therapeutics plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for SLN
Silence Therapeutics plc currently has a Wall Street Score of 23/100. The stored market price is $13.02. Its financial score is 26/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Silence Therapeutics plc does
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another ke
SLN financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $13.02
- Market capitalization:
- $615.0M
- Revenue:
- $921K
- Net income:
- $-85.2M
- Free cash flow:
- $-62.3M
- Cash:
- $5.7M
- Total debt:
- $136K
- EPS:
- -1.89
- Financial score:
- 26/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.6%.
- Free cash flow is $-62.3M, showing cash burn in the current stored period.
- The balance sheet shows $5.7M of cash versus $136K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SLN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.